Anti-interleukin 17A therapy inhibits tumour necrosis factor-mediated bone loss by modulation of T cell balance. (9th March 2010) - Polzer, K; Koenders, M; Baum, W; Patakas, A; Mcinnes, I; Joosten, L; Schett, G; van den Berg, W; Zwerina, J